Peptides derived from platelet non-integrin collagen-receptors or types I and III collagen inhibit collagen-platelet interaction

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 1, 2007, Pages 71-75

  Chiang, Thomas M ^a,b   Zhu, J ^a   Woo Rasberry, Virginia ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

And platelet; Collagen; Nonintegrin receptor; Peptide inhibitor; Platelet adhesion; Platelet aggregation inhibitor; Platelet collagen receptors

Indexed keywords

ARGININE; ASPARTIC ACID; COLLAGEN; COLLAGEN RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCINE; PEPTIDE; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; SERINE; THROMBOCYTE RECEPTOR;

ACUTE CORONARY SYNDROME; BLOOD VESSEL INJURY; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG POTENCY; HEMOSTASIS; HUMAN; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOLOGICAL BLOCKING; PROTEIN BINDING; PROTEIN INTERACTION; RABBIT; REVIEW; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 33947132563     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907780059056     Document Type: Review

References (38)

1. Fitzsimmons, C.M.; Cawston, T.E.; Barnes, M.J. The reactivity of collagen type I: Evidence for multiple platelet-reactive sites in type I collagen molecule. Thromb. and Haemost., 1986, 56, 95-99.
2. Morton, L.F.; Fitzsimmons, C.M.; Rauterberg, J.; Barnes, M. J. Platelet-reactive sites in collagen: Collagens I and III possess different aggregatory sites. Biochem. J., 1987, 248, 483-487.
3. Staatz, W.D.; Walsh, J.J.; Pexton, T.; Santoro, S.A. The α2ß1 integrin cell surface collagen receptor binds to the α1(I)-CB3 peptide of collagen. J. Biol. Chem., 1990, 265, 4778-4781.
4. Staatz, W.D.; Fok, K.F.; Zutter, M.M.; Adams, S.P.; Rodriguez, B.A.; Santoro, S.A. Identification of a tetrapeptide recognition sequence for the α2ß1 integrin in collagen. J. Biol. Chem., 1991, 266, 7363-7367.
5. Knight, C.G.; Morton, L.F.; Peachey, A.R.; Tuckwell, D.S.; Farndale, R.W.; Barnes, M.J. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem., 2000, 275, 35-40.
6. Morton, L.F.; Hargreaves, P.G.; Farndale, R.W.; Young, R.D.; Branes, M.J. Integrin α2ß1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for α2ß1-independent platelet activity. Biochem. J., 1995, 306, 337-344.
7. Chiang, T.M.; Kang, A.H. A synthetic peptide derived from the sequence of type I collagen receptor inhibits type I collagen-mediated platelet aggregation. J. Clin. Invest., 1997, 100, 2079-2084.
8. Chiang, T.M. A nonapeptide derived from the cloned platelet type I collagen receptor inhibits type I collagen-platelet interaction. Am. J. Med. Sci., 2000, 320, 362-367.
9. Chiang, T.M.; Woo-Rasberry, V.; Cole, F. Cloning, characterization, and functional studies of a 47-kDa platelet receptor for type III collagen. J. Biol. Chem., 2002, 277, 34896-34901.
10. Monnet, M.; Fauvel-Lafeve, F. A new platelet receptor specific to type III collagen. Type III collagen-binding protein. J. Biol. Chem., 2000, 275, 10912-10917.
11. Maurice, P.; Waeckel, L.; Pires, V.; Sonnet, P.; Lemesle, M.; Arbeille, B.; Vassy, J.; Rochette, J.; Legrand, C.; Fauvel-Lafeve, F. The platelet receptor for type III collagen (TIIICBP) is present in platelet membrane. Histochem. Cell Biol., 2005, 5, 1-11.
12. Kunicki, T.J.; Nugent, D.J.; Staatz, S.J.; Okchekowski, R.P.; Wayner, E.A.; Carter, W.G. The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and it's identical to the platelet GPIa-IIa complex. J. Biol. Chem., 1988, 263, 4516-4519.
13. 2+-dependet adhesion of platelets to collagen. J. Cell. Biol., 1989, 108, 1017-1024.
14. Body, S.C. Platelet activation and interactions with the microvasculature. J. Cardiovasc Pharmacol., 1996, 27, S13-S25.
15. Curley, G.P.; Blum, H.; Humphries, M.J. Integrin antagonists. CMLS Cell Mol. Life Sci., 1999, 56, 427-441.
16. Chiang, T.M. Collagen-platelet interaction: platelet non-integrin receptors. Histol. Histopathol., 1999, 14, 579-585.
17. Legrand, Y.J.; Karniguian, A.; Le Francier, P.; Fauvel, F.; Caen, J.P. Evidence that a collagen-peptide is a specific inhibitor of platelet-collagen interaction. Biochem. Biophys. Res. Commun., 1980, 96, 1579-1585.
18. Fauvel, F.; Legrand, Y.J.; Bentz, H.; Fietzek, P.P.; Kuhn, K.; Caen, J.P. Platelet-collagen interaction: adhesion of human blood platelets to purified (CB4) peptide for type III collagen. Thromb. Res., 1978, 12, 841-850.
19. Katzman, R.L.; Beachey, E.H.; Kang, A.H. Collagen-induced platelet aggregation: Involvement of an active peptide fragment (α1-CB5). J. Biol. Chem., 1973, 181, 670-672.
20. Balleisen, L.; Nowack, H.; Gay, S.; Timple, R. Inhibition of collagen-induced platelet aggregation by antibodies to distinct types of collagen. Biochem. J., 1979, 184, 683-687.
21. Raynal, N.; Hamaia, S.W.; Siljander, P.R.; Maddox, B.; Peachey, A.R.; Fernandez, R.; Foley, L.J.; Slatter, D.A.; Jarvis, G.E.; Farndale, R.W. The use of synthetic peptides to locate novel integrin alpha 2 beta 1-binding motifs in human collagen III. J. Biol. Chem., 2005, 281, 3821-3831.
22. Maurice, P.; Pires, V.; Amant, C.; Kauskot, A.; Da Nascimento, S.; Sonnet, P.; Rochette, J.; Legrand, C.; Fauvel-Lafeve, F.; Bonnefoy, A. Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse. Vascul. Pharmacol., 2005, 44, 42-49.
23. Gartner, T. K.; Bennett, J. S. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activate platelets. J. Biol. Chem., 1985, 260, 11891-11894.
24. Santoro, S.A.; Zutter, M.M.; Wu, J.E.; Staatz, W.D.; Saelman, E.U.M.; Kelley, P.J. Analysis of collagen receptors. Meth. Enzymol., 1994, 245, 147-183.
25. Zhu, J.; Cole, F.; Woo-Rasberry, V.; Fang, X.R.; Chiang, T.M. Platelet receptors for type I and type III collagens: evidences support type specific active peptides. Thromb. Res., 2007, 119, 111-119.
26. Leclerc, J.R. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical and future directions. Crit. Care Med., 2002, 30, S332.
27. Casserly, I.P.; Topol, E.J. Glycoprotein IIb/IIIa antagonists - from bench to practice. CMLS, Cell Mol. Life Sci., 2002, 59, 478-500.
28. Quinn, M.J.; Plow, E.F.; Topel, E.J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation, 2002, 106, 379-385.
29. Boersma, W.E.; Harrington, R.A.; Moliterno, D.J.; White, H.; Theroux, P.; Van de Werf, F.; de Torbal, A.; Armstrong, P.W.; Wallentin, L.C.; Wilcox, R.G.; Simes, J.; Califf, R.M.; Topol, E.J. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trails. Lancet, 2002, 359, 189-198.
30. Gowda, R.M.; Khan, I.A.; Vasavada, B.C.; Sacchi, T.J.; Reversible myocardial dysfunction: basics and evaluation. Int. J. Cardiol., 2004, 97, 349-353.
31. Maree, A.; Fitzgerald, D.J. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we know? Semin. Vasc. Med., 2003, 3, 385-390.
32. Rossi, M.L.; Zavalloni, D. Inhibitors of platelet glycoprotein IIb/IIIa receprtor:rational for either use in clinical cardiology. Mini Rev. Med. Chem., 2004, 7, 703-709.
33. Cannon, C.P. Learning from the recently completed oral glycoprotein IIb/ IIIa receptor antagonist trails. Clin. Cardiol., 2000, 23 (Suppl. 6), VI-14-17.
34. Kereiakes, D.J. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Am. Heart J, 1999, 138, S39.
35. O'Shea, J.C.; Buller, C.J.; Cantor, W.J. etc. for the ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA, 2002, 287, 618.
36. De Luca, G.; Suryapranata, H.; Stone, G.W.; Antoniucci, D.; Tcheng, J.E.; Neumann, F-J.; Van de Werf, F.; Antman, E.M.; Topol, E.J. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infraction: A meta-regression analysis of randomized trials. JAMA, 2005, 293, 1759.
37. De Luca, G.; Suryapranata, H.; Stone, G.W.; Antoniucci, D.; Tcheng, J.E.; Neumann, F.J.; Bonizzoni, E.; Topol, E.J.; Chiariello, M. Relationship between patient's risk profile and benefits in mortaility from adjunctive abciximab to mechanical for ST-segment elevation myocardical infraction: A meta-analysis of randomized trials. J. Am. Coll. Cardiol, 2006, 47, 685-686.
38. Shpilberg, O.; Rabi, I.; Schiller, K.; Walden, K.; Harats, D.; Tyrell, K.S.; Coller, B.; Seligsohn, U. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are not protected from atherosclerosis. Circulation, 2002, 105, 1044-1048.